(J I D P T S)
ISSN(O):2581-6934

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR QUANTITATIVE ESTIMATION OF DEUCRAVACITINIB IN PURE FORM AND MARKETED PHARMACEUTICAL FORMULATION

Bonagiri Sreedevi[1]*, Pakala Lakuma Devi[2], Guguloth Lava Kumar[3], Thati Jithya[4], Vemireddy Lakshma Reddy[5], Hemanth Dasari[6]

[1]Associate Professor, [2]Students

[2 to 6] Department of Pharmaceutical Chemistry,

[2 to 6] Teegala Ram Reddy College of Pharmacy, #4-202, Meerpet, Balapur (M), Ranga Reddy Dist, Telangana, India-500097

Corresponding Author: Bonagiri Sreedevi ,

Associate Professor, Department of Pharmaceutical Chemistry

Teegala Ram Reddy College of Pharmacy, #4-202, Meerpet, Balapur (M), Ranga Reddy Dist, Telangana, India-500097

Abstract: A simple, rapid, specific and accurate reverse phase high performance liquid chromatographic method has been developed for the validated of Deucravacitinib in bulk as well as in marketed pharmaceutical dosage form. This separation was performed on a Develosil ODS C18 (4.6mm×250mm, 5µm) column with Acetonitrile: Phosphate Buffer (45:55%) v/v as mobile phase at a flow rate of 1.0 mL min−1 with UV detection at 235 nm; the constant column temperature was Ambient. The run time under these chromatographic conditions was less than 8 min. The retention time of Deucravacitinib was found to be 2.267min. The calibration plot was linear over the concentration range of 6–14 µg mL−1 with limits of detection and quantification values of 1.2 and 3.6 ng mL−1 respectively. The mean % assay of marketed formulation was found to be 99.86%, and % recovery was observed in the range of 98-102%. Relative standard deviation for the precision study was found <2%.The developed method is simple, precise, specific, accurate and rapid, making it suitable for estimation of Deucravacitinib in bulk and marketed pharmaceutical dosage form dosage form.

Keywords: Deucravacitinib, RP-HPLC, Method Development, Validation, ICH Guidelines.

INTRODUCTION

Deucravacitinib is a small molecule inhibitor of tyrosine kinase 2 that is used in the treatment of moderate-to-severe plaque psoriasis. Deucravacitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has not been linked instances of clinically apparent acute liver injury1. Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants. It is also indicated for the treatment of psoriatic arthritis in adults. Deucravacitinib (marketed under the brand name Sotyktu) is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor2. It works by decreasing the activity of the immune system to interrupt the inflammatory pathways that cause skin and joint diseases. The IUPAC Name of Deucravacitinib is 6-(cyclo propane carbonyl amino)-4-[2-methoxy-3-(1-methyl-1, 2, 4-triazol-3-yl) anilino]-N-(trideuterio methyl) pyridazine-3-carboxamide3. The Chemical Structure of Deucravacitinib is shown in follows.

All rights reserved by www.jidps.com




Fig-1: Chemical Structure of Deucravacitinib

The considerable literature survey disclose that the analytical methods reported for estimation of Deucravacitinib alone and in combination with other drug, but no analytical methods was reported for estimation of Deucravacitinib28-30. So, it was thought of interest to develop simple, accurate, precise and reproducible RP-HPLC method for estimation of Deucravacitinib in their bulk form and Marketed Pharmaceutical Dosage forms. Methods were validated as per ICH guidelines27 [Q2 (R1)].

MATERIALS AND METHODS

Table-1: Instruments Used

S. No.	Instruments and Glass wares	Model
1	HPLC	WATERS Alliance 2695 separation module, Software: Empower 2, 996 PDA detector.
2	pH meter	Lab India
3	Weighing machine	Sartorius
4	Volumetric flasks	Borosil
5	Pipettes and Burettes	Borosil
6	Beakers	Borosil
7	Digital ultra sonicator	Labman

Table-2: Chemicals Used

S.No.	Chemical	Brand Names
1	Deucravacitinib	Synpharma Research Lab, Hyderabad
2	Water and Methanol for HPLC	LICHROSOLV (MERCK)
3	Acetonitrile for HPLC	Merck

HPLC METHOD DEVELOPMENT:

Preparation of Standard Solution:

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Methanol and sonicate to dissolve and removal of air completely and make volume up to the mark with the same Methanol. Further pipette 0.1ml of the above Deucravacitinib stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Procedure:

Inject the samples by changing the chromatographic conditions and record the chromatograms, note the conditions of proper peak elution for performing validation parameters as per ICH guidelines.

Mobile Phase Optimization:

Initially the mobile phase tried was Methanol and Methanol: Water with varying proportions. Finally, the mobile phase was optimized to Acetonitrile: Phosphate Buffer in proportion 45:55% v/v.

Optimization of Column:

The method was performed with various C18 columns like, X-bridge column, Xterra, and C18 column. Develosil ODS C18 (4.6 x 250mm, 5µm) was found to be ideal as it gave good peak shape and resolution at 1ml/min flow.

Preparation of Potassium dihydrogen Phosphate (KH_2PO_4) buffer (pH-2.8):

Dissolve 6.8043 of potassium dihydrogen phosphate in 1000 ml HPLC water and adjust the pH 2.8 with diluted orthophosphoric acid. Filter and sonicate the solution by vacuum filtration and ultra-sonication4.

Preparation of Mobile Phase:

Accurately measured 450 ml (45%) of Acetonitrile, 550 ml of Phosphate buffer (55%) were mixed and degassed in digital ultra sonicater for 15 minutes and then filtered through 0.45 µ filter under vacuum filtration.

Diluent Preparation:

The Mobile phase5 was used as the diluent.

Method Validation Parameters

System Suitability

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same

solvent. (Stock solution) Further pipette 0.1ml of the above Deucravacitinib stock solution into a 10ml volumetric flask and dilute up to the mark with diluents.

Procedure:

The standard solution was injected for five times and measured the area for all five injections in HPLC. The %RSD for the area of five replicate injections was found to be within the specified limits.

Specificity:

Preparation of Standard Solution:

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 0.1ml of the above Deucravacitinib stock solutions into a 10ml volumetric flask and dilute up to the mark with diluents.

Preparation of Sample Solution:

Weight 10 mg equivalent weight of Deucravacitinib sample into a 10mL clean dry volumetric flask and add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent. Further pipette 0.1ml of Deucravacitinib above stock solution into a 10ml volumetric flask and dilute up to the mark with diluent.

Procedure:

Inject the three replicate injections of standard and sample solutions and calculate the assay by using formula:

$$\%ASSAY = \frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

Linearity and Range:

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Preparation of Level – I (6ppm of Deucravacitinib):

Take 0.6ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluents and sonicate the solution for bubble entrapment using ultrasonicator.

Preparation of Level – II (8ppm of Deucravacitinib):

Take 0.8ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluents and sonicate the solution for bubble entrapment using ultrasonicator.

Preparation of Level – III (10ppm of Deucravacitinib):

Take 0.1ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluents and sonicate the solution for bubble entrapment using ultrasonicator.

Preparation of Level – IV (12ppm of Deucravacitinib):

Take 0.12ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluents and sonicate the solution for bubble entrapment using ultrasonicator.

Preparation of Level – V (14ppm of Deucravacitinib):

Take 0.14ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluents and sonicate the solution for bubble entrapment using ultrasonicator.

Procedure:

Inject each level into the chromatographic system and measure the peak area.

Plot a graph of peak area versus concentration (on X-axis concentration and on Y-axis Peak area) and calculate the correlation coefficient6.

Precision

Repeatability

Preparation of Deucravacitinib Product Solution for Precision:

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Further pipette 0.1ml of the above Deucravacitinib stock solutions into a 10ml volumetric flask and dilute up to the mark with diluents.

Procedure:

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Intermediate Precision:

To evaluate the intermediate precision (also known as Ruggedness) of the method, Precision was performed on different days by maintaining same conditions.

Procedure:

Analyst 1:

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Analyst 2:

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Accuracy:

For preparation of 50% Standard Stock Solution:

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 0.05ml of the above Deucravacitinib stock solution into a 10ml volumetric flask and dilute up to the mark with diluents.

For preparation of 100% Standard Stock Solution:

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 0.1ml of the above Deucravacitinib stock solution into a 10ml volumetric flask and dilute up to the mark with diluents.

For preparation of 150% Standard Stock Solution:

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 0.15ml of the above Deucravacitinib stock solution into a 10ml volumetric flask and dilute up to the mark with diluents.

Procedure:

Inject the Three replicate injections of individual concentrations (50%, 100%, 150%) were made under the optimized conditions. Recorded the chromatograms and measured the peak responses. Calculate the Amount found and Amount added for Deucravacitinib and calculate the individual recovery and mean recovery values.

Limit of Detection and Limit of Quantification (LOD & LOQ):

Preparation of 0.95µg/ml Solution (For LOD):

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 0.0095ml of the above Deucravacitinib stock solutions into a 10ml volumetric flask and dilute up to the mark with diluents.

Preparation of 2.9µg/ml Solution (For LOQ):

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 0.029ml of the above Deucravacitinib stock solutions into a 10ml volumetric flask and dilute up to the mark with diluents.

Robustness:

The analysis was performed in different conditions to find the variability of test results. The following conditions are checked for variation of results. .

For preparation of Standard solution:

Accurately weigh and transfer 10 mg of Deucravacitinib working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 0.1ml of the above Deucravacitinib stock solution into a 10ml volumetric flask and dilute up to the mark with diluents.

Effect of Variation of Flow Conditions:

The sample was analyzed at 0.9 ml/min and 1.1 ml/min instead of 1ml/min, remaining conditions are same. 10µl of the above sample was injected and chromatograms were recorded.

Effect of Variation of Mobile Phase Organic Composition:

The sample was analyzed by variation of mobile phase i.e. Methanol: Phosphate Buffer was taken in the ratio and 40:60, 30:70 instead (35:65), remaining conditions are same. 10µl of the above sample was injected and chromatograms were recorded.

RESULTS AND DISCUSSION

Optimization of Method:

The method development process was carried out by performing several preliminary trials to establish suitable chromatographic conditions for the effective separation and accurate estimation of the selected drug. Various chromatographic parameters, including mobile phase composition, column selection, flow rate, detection wavelength, and analysis time, were considered during the optimization process. The mobile phase composition was optimized using acetonitrile and phosphate buffer in a ratio of 45:55 (v/v), which was selected to obtain satisfactory chromatographic performance. A Develosil ODS C18 column (4.6 × 250 mm, 5 µm) was used as the stationary phase to achieve effective separation of the analyte. The chromatographic analysis was performed at ambient column temperature with a flow rate of 1.0 mL/min. The detection wavelength was set at 235 nm to monitor the drug response, and an injection volume of 10 µL was maintained throughout the analysis. The total chromatographic run time was fixed at 8 minutes to complete the analysis within a suitable period. These optimized chromatographic conditions were selected for further analytical method validation, including linearity, accuracy, precision and other relevant validation parameters, to assess the suitability of the developed method for routine pharmaceutical analysis.




Fig-2: Optimized Chromatographic Condition

Method Validation

The developed RP-HPLC method was validated according to ICH guidelines to ensure its accuracy, precision, reliability, and suitability for the quantitative estimation of the selected drug. The validation parameters included system suitability, specificity, linearity, accuracy, precision, LOD, LOQ, and robustness.

System Suitability:

The test was carried out by making five replicate injections of a standard solution containing 10µg/ml of Deucravacitinib and analyzing each solute for their peak area, theoretical plates (N), tailing factor (T) and asymmetric factors (As). The results of System Suitability test7 were shown in table-3.

Table-3: Results of System Suitability for Deucravacitinib

S.No.	Peak Name	RT	Area (µV*sec)	Height (µV)	USP Plate Count	USP Tailing
1	Deucravacitinib	2.277	1652847	185647	6589	1.24
2	Deucravacitinib	2.277	1653658	186254	6587	1.26
3	Deucravacitinib	2.267	1654521	185475	6584	1.28
4	Deucravacitinib	2.265	1653564	186594	6582	1.29
5	Deucravacitinib	2.277	1658745	185684	6895	1.24
Mean			1654667			
Std. Dev.			2355.764			
% RSD			0.142371			

Specificity

The ICH documents define specificity8 as the ability to assess unequivocally the analyte in the presence of components that may be expected to be present, such as impurities, degradation products, and matrix components. Analytical method was tested for specificity to measure accurately quantitates Deucravacitinib in drug product.

$$\%ASSAY = \frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

$$= 99.40\%$$

The % purity9 of Deucravacitinib in pharmaceutical dosage form was found to be 99.40%.

Linearity

The linearity of the developed method was evaluated by processing five different concentration levels of Deucravacitinib over the concentration of 6 to 14µg/mL. The linearity10 plots were acquired by plotting peak response (on X-axis) vs. concentration (on Y-axis). The results of the

linearity and calibration curve11 were represented in Table 4, and Fig-3.

Table-4: Data for Linearity of Deucravacitinib

Concentration µg/ml	Average Peak Area
6	1078475
8	1461129
10	1808358
12	2211573
14	2593778




Fig-3: Linearity Curve of Deucravacitinib

Linearity Plot: The plot of Concentration (x) versus the Average Peak Area (y) data of Deucravacitinib is a straight line.

Y = mx + c

Slope (m) = 18500

Intercept (c) = 16179

Correlation Coefficient (r) = 0.999

Validation Criteria: The response linearity is verified if the Correlation Coefficient is 0.99 or greater.

Conclusion: Correlation Coefficient (r) is 0.99, and the intercept is 0.16179. These values meet the validation criteria.

Precision:

The precision12 of an analytical procedure expresses the closeness of agreement (degree of scatter) between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions.

Repeatability: Obtained Six (6) replicates of 100% accuracy13 solution as per experimental conditions. Recorded the peak areas and calculated % RSD and results were shown in table-5.

Table-5: Results of Repeatability for Deucravacitinib:

S. No.	Peak name	Retention time	Area (µV*sec)	Height (µV)	USP Plate Count	USP Tailing
1	Deucravacitinib	2.293	1658954	186958	1.26	6785
2	Deucravacitinib	2.276	1658745	187548	1.27	6854
3	Deucravacitinib	2.286	1659865	189854	1.26	6852
4	Deucravacitinib	2.277	1653254	186985	1.25	6784
5	Deucravacitinib	2.280	1654781	189542	1.24	6895
6	Deucravacitinib	2.293	1661324	187586	1.28	6965
Mean			1657821			
Std. Dev			3120.433			
%RSD			0.188225			

Intermediate Precision14:

Analyst1:

Table-6: Results of Intermediate Precision Analyst 1 for Deucravacitinib

S. No.	Peak Name	RT	Area (µV*sec)	Height (µV)	USP Plate Count	USP Tailing
1	Deucravacitinib	2.274	1678541	186589	6587	1.26
2	Deucravacitinib	2.258	1685985	186598	6321	1.26
3	Deucravacitinib	2.267	1685745	186985	6385	1.25
4	Deucravacitinib	2.270	1685987	187854	6580	1.26
5	Deucravacitinib	2.264	1698526	187549	6721	1.27
6	Deucravacitinib	2.265	1685943	186598	6637	1.26
Mean			1686788			
Std. Dev			6463.466			
% RSD			0.383182			

Analyst 2:

Table-7: Results of Intermediate Precision Analyst 2 for Deucravacitinib

S. No.	Peak Name	RT	Area (µV*sec)	Height (µV)	USP Plate count	USP Tailing
1	Deucravacitinib	2.277	1665847	167481	6854	1.25
2	Deucravacitinib	2.255	1658989	167854	6785	1.26
3	Deucravacitinib	2.265	1659845	167895	6854	1.24
4	Deucravacitinib	2.255	1665964	167854	6895	1.26
5	Deucravacitinib	2.253	1659863	168585	6459	1.25
6	Deucravacitinib	2.252	1665986	167859	6456	1.26
Mean			1662749			
Std. Dev			3501.766			
% RSD			0.210601			

Accuracy

Method accuracy15 was estimated at three variable concentrations of 50%, 100%, and 150% levels by spiking the known amount of the drug analytes. The % recovery16-18 at each level was calculated, and the findings were represented in Table 8.

Table-8: The Accuracy Results for Deucravacitinib

%Concentration (at specification Level)	Area	Amount Added (ppm)	Amount Found (ppm)	% Recovery	Mean Recovery
50%	109068.3	5	5.021	100.420%	100.72%
100%	202187	10	10.054	100.540%	
150%	297032.3	15	15.181	101.206%	

Limit of Detection

The detection limit19 of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value.

LOD= 3.3 × σ / s

Where

σ = Standard deviation20 of the response

S = Slope of the calibration curve

Result:

= 0.95µg/ml

Quantitation Limit

The quantitation limit21 of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined.

LOQ=10×σ/S

Where

σ = Standard deviation of the response

S = Slope of the calibration curve22

Result:

= 2.9µg/ml

Robustness:

The robustness23 was performed for the flow rate variations from 0.9 ml/min to 1.1ml/min and mobile phase ratio variation from more organic phase to less organic phase ratio for Deucravacitinib. The method is robust only in less flow condition. The standard of Deucravacitinib was injected by changing the conditions of chromatography24. There was no significant change in the parameters like resolution, tailing factor, asymmetric factor, and plate count.

Table-9: Results for Robustness of Deucravacitinib

Parameter Used for Sample Analysis	Peak Area	Retention Time	Theoretical Plates	Tailing factor
Actual Flow rate of 1.0 mL/min	1658242	2.312	6569	1.24
Less Flow rate of 0.9 mL/min	1854215	2.458	6865	1.35
More Flow rate of 1.1 mL/min	1758468	2.032	6254	1.32

SUMMARY AND CONCLUSION

The analytical method was developed by studying different parameters. First of all, maximum absorbance was found to be at 235nm and the peak purity was excellent. Injection volume was selected to be 10µl which gave a good peak area. The column used for study was Develosil ODS C18 (4.6×250mm, 5µm) because it was giving good peak. Ambient temperature was found to be suitable for the nature of drug solution. The flow rate was fixed at 1.0ml/min because of good peak area and satisfactory retention time. Mobile phase is Acetonitrile: Phosphate Buffer pH-2.8 in the ratio of 45:55 v/v was fixed due to good symmetrical peak. So this mobile phase was used for the proposed study. Methanol was selected because of maximum extraction sonication time was fixed to be 10min at which all the drug particles were completely soluble and showed good recovery. Run time was selected to be 8min because analyze gave peak around 2.267min and also to reduce the total run time. The percent recovery was found to be 98.0-102 was linear and precise over the same range. Both system and method precision was found to be accurate and well within range. The analytical method was found linearity over the range of 6-14ppm of the Deucravacitinib target concentration. The analytical passed both robustness and ruggedness tests. On both cases, relative standard deviation was well satisfactory.

BIBLIOGRAPHY

[1]. https://go.drugbank.com/drugs/DB16650

[2]. https://pubchem.ncbi.nlm.nih.gov/compound/Deucravacitinib

[3]. https://en.wikipedia.org/wiki/Deucravacitinib

[4]. Dr. Kealey and P.J Haines, Analytical Chemistry, 1stedition, Bios Publisher, (2002), P1-7.

A.Braith Wait and F. J. Smith, Chromatographic Methods, 5th edition, Kluwer Academic Publisher, (1996), PP 1-2.

[5]. Andrea Weston and Phyllisr. Brown, HPLC Principle and Practice, 1st edition, Academic press, (1997), PP 24-37.

[6]. Yuri Kazakevich and Rosario Lobrutto, HPLC for Pharmaceutical Scientists, 1stedition, Wiley Interscience A John Wiley & Sons, Inc., Publication, (2007), PP 15-23.

[7]. Chromatography, (online). URL : http : // en.wikipedia.org / wiki / Chromatography.

[8]. Meyer V.R. Practical High-Performance Liquid Chromatography, 4th Ed. England, John Wiley & Sons Ltd, (2004), PP 7-8.

[9]. Sahajwalla CG a new drug development, Vol 141, Marcel Dekker Inc., New York, (2004), PP 421–426.

[10]. Introduction to Column. (Online),URL:http://amitpatel745.topcities.com/index_files/study/column care.pdf

[11]. Detectors used in HPLC (online)URL:http://wiki.answers.com/Q/What_detectors_are_used_in_HPLC

[12]. Detectors (online) ,URL:http://hplc.chem.shu.edu/NEW/HPLC_Book/Detectors/det_uvda.html

[13]. Detectors (online) ,URL:http://www.dionex.com/enus/webdocs/64842-31644-02_PDA-100.pdf

[14]. Detectors (online),URL:http://www.ncbi.nlm.nih.gov/pubmed/8867705

[15]. Detectors (online),URL:http://www.chem.agilent.com/Library/applications/59643559.pdf

[16]. Detectors (online),URL:http://hplc.chem.shu.edu/new/hplcbook/detector

[17]. Draft ICH Guidelines on Validation of Analytical Procedures Definitions and terminology. Federal Register, Vol 60. IFPMA, Switzerland, (1995), PP 1126.

[18]. Code Q2B, Validation of Analytical Procedures; Methodology. ICH Harmonized Tripartite Guidelines, Geneva, Switzerland, (1996), PP 1- 8.

[19]. Introduction to analytical method validation (online), available from: URL: http : // www . standardbase.hu / tech / HPLC % 20 validation % 20PE.pdf.

[20]. Data elements required for assay validation, (online) available from: URL: http : // www . labcompliance.com / tutorial / methods/default.aspx.

[21]. Snyder LR practical HPLC method development, 2nd edition. John Wiley and sons, New York, (1997), PP 180-182.

[22]. Skoog D A, West D M, Holler FJ: Introduction of analytical chemistry. Sounder college of publishing, Harcourt Brace college publishers. (1994), PP 1-5.

[23]. Sharma B K, Instrumental method of chemical analysis Meerut. (1999), PP 175-203.

[24]. Breaux J and Jones K: Understanding and implementing efficient analytical method development and validation. Journal of Pharmaceutical Technology (2003), 5, PP 110-114.

[25]. Willard, H. y. Merritt L.L, Dean J.A and Settle F.A "Instrumental Methods of Analysis" 7th edition CBS publisher and distributors, New Delhi, (1991), PP 436-439.

[26]. ICH Q2A, "Validation of Analytical Methods, Definitions and Terminology", ICH Harmonized tripartite guideline, (1999).

[27]. Pottabattula Mahesh 1, M Akiful Haque 1, Baher I Salman 2, Tarek S Belal 3, Adel Ehab Ibrahim 4,5, Sami El Deeb, Fast and Sensitive Bioanalytical Method for the Determination of Deucravacitinib in Human Plasma Using HPLC-MS/MS: Application and Greenness Evaluation, Molecules. 2023 Jul 17; 28(14): 5471. Doi: 10.3390/molecules28145471.

[28]. Vijaya Madhyanapu Golla, Rahul Khemchandani, Sowmya Chaganti, Gananadhamu Samanthula, Separation and characterization of hydrolytic degradation product of Deucravacitinib by validated high-performance liquid chromatography method and liquid chromatography-mass spectrometry, SSC Plus Separation Science Plus, Volume7, Issue5, May 2024, https://doi.org/10.1002/sscp.202300180Digital Object Identifier (DOI).

[29]. Jabeen Nameera, Tejasree A., Keerthana A., Shruthika G., Tharun K. and Bandla Jahnavi*, UV Spectrophotometric Approach for the Determination of Deucravacitinib in Pharmaceutical Dosage Form: Development and Validation, International Journal of Zoological Investigations Vol. 10, No. 2, 1234-1239 (2024).